Back to Search
Start Over
Investigation of double carbapenem efficiency in experimental sepsis of colistin resistant Klebsiella pneumoniae
- Publication Year :
- 2021
-
Abstract
- OBJECTIVE Klebsiella pneumoniae, a Gram-negative pathogen, especially which produces carbapenemase, is seen as a major threat to public health due to rapid plasmid-mediated spread of resistance and limited therapeutic options available for treatment. Although colistin has been recognized as a "last resort" antimicrobial for multidrug-resistant K. pneumoniae infections, these isolates have developed resistance to colistin as a result of its intensive use. The aim of this study was to evaluate the efficacy of double-carbapenem treatment of colistin-resistant K. pneumoniae experimental sepsis in mice. METHODS In the study, 8-10-week-old Balb-c mice were divided as control groups (positive and negative) and treatment groups (colistin, ertapenem+meropenem, and ertapenem+meropenem+colistin). Sepsis was developed in mice by an intraperitoneal injection of colistin resistant K. pneumoniae. Antibiotics were given intraperitoneally 3 h after bacterial inoculation. Mice in each subgroup were sacrificed with overdose anesthetic at the end of 24-48 h and cultures were made from the heart, lung, liver, and spleen. Furthermore, homogenates of lung and liver were used to detect the number of colony-forming units per gram. Bacterial clearance was evaluated in lung and liver at different time points. RESULTS When the quantitative bacterial loads in the lung and liver tissues are evaluated, no statistically significant difference was observed between different antibiotic treatments (p>0.05). All three treatment options were not effective, especially in 24 h. Only the decrease in bacterial load at the 48th h of the group treated with ertapenem + meropenem + colistin was found significant (p
- Subjects :
- 0301 basic medicine
Carbapenem
Klebsiella pneumoniae
medicine.drug_class
030106 microbiology
Antibiotics
Meropenem
Microbiology
Sepsis
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
medicine
polycyclic compounds
030212 general & internal medicine
biology
business.industry
biochemical phenomena, metabolism, and nutrition
Antimicrobial
biology.organism_classification
medicine.disease
bacterial infections and mycoses
chemistry
Colistin
bacteria
business
General Economics, Econometrics and Finance
Ertapenem
medicine.drug
Subjects
Details
- Language :
- Turkish
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....e2ebe86b96d6ca619e007d02b4cdfd3b